期刊文献+

左旋奥硝唑及磷酸左奥硝唑酯二钠在大鼠体内药代动力学比较研究 被引量:2

Pharmacokinetics of(S)-ornidazole and(S)-ornidazole phosphate disodium in rats
下载PDF
导出
摘要 采用手性色谱LC-MS/MS法同时检测左旋和右旋奥硝唑,比较研究左旋奥硝唑[(S)-ONZ]及磷酸左奥硝唑酯二钠[(S)-ONZ-P]在大鼠体内的药代动力学差异,并监测是否发生手性转化。结果表明,大鼠单次iv给予25,50,100 mg/kg(S)-ONZ及等物质的量(S)-ONZ-P后,(S)-ONZ-P在SD大鼠体内迅速转化为(S)-ONZ,平均转化时间介于1.57-3.86 min。两组大鼠血浆中(S)-ONZ的t1/2分别为2.04-2.31 h;2.02-2.51 h;AUC0-∞与剂量间呈良好的线性关系,呈线性动力学过程。(S)-ONZ,(S)-ONZ-P在大鼠体内药代动力学行为无显著差异,且二者均不转化生成(R)-ONZ。 The aims of this study were to conduct the comparative evaluation of pharmacokinetic of (S)-ornidazole [ (S) -ONZ] and (S) -ornidazole phosphate disodium [ (S) ONZ-P] in rats, and to observe the potentialchiral transformation to (R) -ornidazole [ (R) -ONZ] using developed LC-MS/MS method. After single, intravenousadministration of 25, 50, 100 mg/kg (S) -ONZ and(S) -ONZ-P [ equal molarity to that of (S) -ONZ], it was foundthat there existed linearity between the calculated areas under the curve (AUC0 ) and dose. And eliminationhalf-time (t1/2) of (S) -ONZ was calculated to be 2.04-2.31 h and 2.02-2.51 h, respectively. After iv dosing of(S) -ONZ-P, (S) -ONZ-P quickly transferred into (S) -ONZ with the average transformation time of around 1.57 to3.86 min. No significant differences in pharmacokinetics between the two drugs were found in rats. There was no(R)-ONZ detected in the plasma using both (S)-ONZ and (S)-ONZ-P.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2014年第5期571-575,共5页 Journal of China Pharmaceutical University
基金 江苏省药代动力学重点实验室提升项目(No.BM2012012)~~
关键词 左旋奥硝唑 磷酸左奥硝唑酯二钠 LC-MS/MS 药代动力学 (S) -oruidazole (S) -ornidazole phosphate LC-MS/MS pharmacokinetics
  • 相关文献

参考文献14

  • 1Huttunen KM, Raunio H, Rautio J. Prodrugs--from serendipity to rational design [ J ]. Pharmacol Rev ,2011,63 ( 3 ) :750 - 771. 被引量:1
  • 2Zawilska JB, Wojcieszak J, Olejniczak AB. Prodrugs : a challenge for the drug development [ J ]. Pharmaeol Rep, 2013,65 ( 1 ) : 1 -14. 被引量:1
  • 3Stella VJ. Prodrugs : some thoughts and current issues [ J ]. J Pharm Sci ,2010,99( 12 ) :4 755 -4 765. 被引量:1
  • 4Scott 17I, Osterman MT. Medical management of Crohn disease [J]. Clin Colon Rectal Surg ,2013 ,26 ( 2 ) :67 -74. 被引量:1
  • 5Papi C, Fasci SF, Margagnoni G, et al. Randomized controlled tri- als in prevention of postsurgical recurrence in Crohn's disease [J]. Rev Recent Clin Trials,2012,7(4) :307 -413. 被引量:1
  • 6陈珂,孙继红,王志强,季晖.奥硝唑对映体对小鼠中枢抑制作用研究[J].中国药科大学学报,2012,43(3):271-274. 被引量:10
  • 7Jana S, Mandlekar S, Marathe P. Prodrug design to improve phar- macokinetic and drug delivery properties: challenges to the discovery scientists [ J ]. Curt Med Chem, 201 O, 17 ( 32 ) : 3 874 - 3 908. 被引量:1
  • 8Marat DM, Romari Am, Mariela N ,et al. Biomarkers of genotoxic- ity and genomie instability in a non-human primate, Cebus libidi- nosus ( Cebidae, Platyrrhini ), exposed to nitroimidazole deriva- tives[J]. Mutat Res ,2011,721( 1 ) : 108 - 113. 被引量:1
  • 9Menendez D, Rojas E, Herrera LA, et al. DNA breakage due to metronidazole treatment [ J ]. Mutat Res, 2001,478 ( 1/2 ) : 153 - 158. 被引量:1
  • 10Muller J, Schildkneeht P, Muller N. Metabolism of nitro drugs metronidazole and nitazoxanide in Giardia lamblia:characteriza- tion of a novel nitroreductase (G1NR2) [ J ]. J Antimicrob Chemother,2013,68 ( 8 ) : 1 781 - 1 789. 被引量:1

二级参考文献58

共引文献11

同被引文献21

  • 1陈燕,石涛,柳晓泉,钟皎,王广基.左旋和右旋奥硝唑在大鼠体内的药代动力学[J].中国药科大学学报,2006,37(1):41-44. 被引量:14
  • 2Haria M,Bryson HM,Goa KL.Itraconazole.A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections [J].Drugs,1996,51(4):585-620. 被引量:1
  • 3Peng CC,Shi W,Lutz JD,et al.Stereospecific metabolism of itraconazole by CYP3A4:dioxolane ring scission of azole antifungals[J].Drug Metab Dispos,2012,40(3):426-435. 被引量:1
  • 4Thienpont A,Gal J,Aeschlimann C,et al.Studies on stereoselective separations of the “azole” antifungal drugs ketoconazole and itraconazole using HPLC and SFC on silica-based polysaccharides[J].Analusis,1999,27(8):713-718. 被引量:1
  • 5Liu HC,Wang N,Yu Y,et al.Stereoselectivity in trans-tramadol metabolism and tran-O-demethytramadol formation in rat liver microsomes [J].Acta Pharmacol Sin,2003,24(1):85-90. 被引量:1
  • 6Desal MJ,Gill MS,Hsu WH,et al.Pharmacokinetics of theanine enantiomers in rats [J].Chirality,2005,17(3):154-162. 被引量:1
  • 7Beroza P,Suto MJ.Designing chiral libraries of drug discovery [J].Drug Discov Today,2000,5(8):364. 被引量:1
  • 8Eap CB,Lessard E,Baumann P,et al.Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans [J].Pharmacogenetics,2003,13(1):39-47. 被引量:1
  • 9Zhu CJ,Zhang JT.Stereoselective plasma protein binding and target tissue distribution of clausenamide enantiomers in rats[J].Chirality,2009,21(3):402-406. 被引量:1
  • 10Caldwell J.Importance of stereospecific bioanalytical monitoring in drug development [J].J Chromatogr A,1996,719(1):3-13. 被引量:1

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部